Cargando…

Reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation

AIMS: Doxorubicin (DOX)‐induced heart failure has a poor prognosis, and effective treatments have not been established. Because DOX shows cumulative cardiotoxicity, we hypothesized that minimal cardiac remodelling occurred at the initial stage in activating cardiac fibroblasts. Our aim was to invest...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Ryo, Umemura, Masanari, Narikawa, Masatoshi, Hikichi, Mayu, Osaw, Kohei, Fujita, Takayuki, Yokoyama, Utako, Ishigami, Tomoaki, Tamura, Kouichi, Ishikawa, Yoshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160475/
https://www.ncbi.nlm.nih.gov/pubmed/31984667
http://dx.doi.org/10.1002/ehf2.12616
_version_ 1783522761366306816
author Tanaka, Ryo
Umemura, Masanari
Narikawa, Masatoshi
Hikichi, Mayu
Osaw, Kohei
Fujita, Takayuki
Yokoyama, Utako
Ishigami, Tomoaki
Tamura, Kouichi
Ishikawa, Yoshihiro
author_facet Tanaka, Ryo
Umemura, Masanari
Narikawa, Masatoshi
Hikichi, Mayu
Osaw, Kohei
Fujita, Takayuki
Yokoyama, Utako
Ishigami, Tomoaki
Tamura, Kouichi
Ishikawa, Yoshihiro
author_sort Tanaka, Ryo
collection PubMed
description AIMS: Doxorubicin (DOX)‐induced heart failure has a poor prognosis, and effective treatments have not been established. Because DOX shows cumulative cardiotoxicity, we hypothesized that minimal cardiac remodelling occurred at the initial stage in activating cardiac fibroblasts. Our aim was to investigate the initial pathophysiology of DOX‐exposed cardiac fibroblasts and propose prophylaxis. METHODS AND RESULTS: An animal study was performed using a lower dose of DOX (4 mg/kg/week for 3 weeks, i.p.) than a toxic cumulative dose. Histological analysis was performed with terminal deoxynucleotidyl transferase‐mediated dUTP nick‐end labelling assay, picrosirius red staining, and immunohistochemical staining. The mechanism was analysed in vitro with a low dose of DOX, which did not induce cell apoptosis. Microarray analysis was performed. Differentially expressed genes were confirmed by enrichment analysis. Mitochondrial damage was assessed by mitochondrial membrane potential. The production of inflammatory cytokines and fibrosis markers was assessed by western blot, quantitative polymerase chain reaction, and ELISA. A phosphokinase antibody array was performed to detect related signalling pathways. Low‐dose DOX did not induced cell death, and fibrosis was localized to the perivascular area in mice. Microarray analysis suggested that DOX induced genes associated with the innate immune system and inflammatory reactions, resulting in cardiac remodelling. DOX induced mitochondrial damage and increased the expression of interleukin‐1. DOX also promoted the expression of fibrotic markers, such as alpha smooth muscle actin and galectin‐3. These responses were induced through stress‐activated protein kinase/c‐Jun NH2‐terminal kinase signalling. A peroxisome proliferator‐activated receptor (PPARγ) agonist attenuated the expression of fibrotic markers through suppressing stress‐activated protein kinase/c‐Jun NH2‐terminal kinase. Furthermore, this molecule also suppressed DOX‐induced early fibrotic responses in vivo. CONCLUSIONS: Low‐dose DOX provoked reactive fibrosis through sterile inflammation evoked by the damaged mitochondria.
format Online
Article
Text
id pubmed-7160475
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71604752020-04-20 Reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation Tanaka, Ryo Umemura, Masanari Narikawa, Masatoshi Hikichi, Mayu Osaw, Kohei Fujita, Takayuki Yokoyama, Utako Ishigami, Tomoaki Tamura, Kouichi Ishikawa, Yoshihiro ESC Heart Fail Original Research Articles AIMS: Doxorubicin (DOX)‐induced heart failure has a poor prognosis, and effective treatments have not been established. Because DOX shows cumulative cardiotoxicity, we hypothesized that minimal cardiac remodelling occurred at the initial stage in activating cardiac fibroblasts. Our aim was to investigate the initial pathophysiology of DOX‐exposed cardiac fibroblasts and propose prophylaxis. METHODS AND RESULTS: An animal study was performed using a lower dose of DOX (4 mg/kg/week for 3 weeks, i.p.) than a toxic cumulative dose. Histological analysis was performed with terminal deoxynucleotidyl transferase‐mediated dUTP nick‐end labelling assay, picrosirius red staining, and immunohistochemical staining. The mechanism was analysed in vitro with a low dose of DOX, which did not induce cell apoptosis. Microarray analysis was performed. Differentially expressed genes were confirmed by enrichment analysis. Mitochondrial damage was assessed by mitochondrial membrane potential. The production of inflammatory cytokines and fibrosis markers was assessed by western blot, quantitative polymerase chain reaction, and ELISA. A phosphokinase antibody array was performed to detect related signalling pathways. Low‐dose DOX did not induced cell death, and fibrosis was localized to the perivascular area in mice. Microarray analysis suggested that DOX induced genes associated with the innate immune system and inflammatory reactions, resulting in cardiac remodelling. DOX induced mitochondrial damage and increased the expression of interleukin‐1. DOX also promoted the expression of fibrotic markers, such as alpha smooth muscle actin and galectin‐3. These responses were induced through stress‐activated protein kinase/c‐Jun NH2‐terminal kinase signalling. A peroxisome proliferator‐activated receptor (PPARγ) agonist attenuated the expression of fibrotic markers through suppressing stress‐activated protein kinase/c‐Jun NH2‐terminal kinase. Furthermore, this molecule also suppressed DOX‐induced early fibrotic responses in vivo. CONCLUSIONS: Low‐dose DOX provoked reactive fibrosis through sterile inflammation evoked by the damaged mitochondria. John Wiley and Sons Inc. 2020-01-27 /pmc/articles/PMC7160475/ /pubmed/31984667 http://dx.doi.org/10.1002/ehf2.12616 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research Articles
Tanaka, Ryo
Umemura, Masanari
Narikawa, Masatoshi
Hikichi, Mayu
Osaw, Kohei
Fujita, Takayuki
Yokoyama, Utako
Ishigami, Tomoaki
Tamura, Kouichi
Ishikawa, Yoshihiro
Reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation
title Reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation
title_full Reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation
title_fullStr Reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation
title_full_unstemmed Reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation
title_short Reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation
title_sort reactive fibrosis precedes doxorubicin‐induced heart failure through sterile inflammation
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160475/
https://www.ncbi.nlm.nih.gov/pubmed/31984667
http://dx.doi.org/10.1002/ehf2.12616
work_keys_str_mv AT tanakaryo reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation
AT umemuramasanari reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation
AT narikawamasatoshi reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation
AT hikichimayu reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation
AT osawkohei reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation
AT fujitatakayuki reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation
AT yokoyamautako reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation
AT ishigamitomoaki reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation
AT tamurakouichi reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation
AT ishikawayoshihiro reactivefibrosisprecedesdoxorubicininducedheartfailurethroughsterileinflammation